Chuckles759 Sunday, 05/10/20 02:03:27 AM Re: Black-Ops post# 76824 Post # of 93396 Black-Ops, your posts have been very spot on and obviously tempered with wisdom and experience. Just focusing on the HIV treatment here. COVID is a completely different topic and would be awesome if that gets released for treatment ASAP. Since current HIV patients (health care covered) need maintenance drugs to the tune of $15-25K/year, wouldn't a good price point be in the range of $300-$500/dose (one dose per week per year = $15,600 - $26,000) to make it comparable in price but vastly superior in benefit? Not sure of production and delivery costs, but amortizing the costs over a few years to near term debt service and incrementally reward shareholders make sense, IMHO. Do you now if the FDA application for HIV included exclusivity? I know CytoDyn has requested 7-year exclusivity in GvHD in March 2020, but not aware of a request for HIV treatment. These price points are somewhat in alignment with CytoDyn's PRO 140 brief from March 2018 page 3 and 15 (http://content.stockpr.com/cytodyn/media/a142a8575db88331c0585a336ca2ebfd.pdf). I'm trying to pin market share/revenue for each indication....then try to fathom them all added up.